“Bullish on Emcure Pharmaceuticals for the next 1-2 weeks, recommending a buy at ₹1,861 with a target of ₹2,045 and a strict stop loss at ₹1,770. The stock shows strong bullish price action, reversing sharply from 50-day EMA support, forming a higher-low structure with a powerful green candle and a firm daily RSI, favouring continuation.”

Sumeet Bagadia’s track record: 6 graded calls · 95% CI 19–81%